Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  PPD, Inc.    PPD

PPD, INC.

(PPD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In a short-term perspective, the company has interesting fundamentals.
Strengths
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 23.2 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • With an expected P/E ratio at 89.27 and 35.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
PPD, INC.4.79%12 539
MODERNA, INC.19.79%49 468
LONZA GROUP AG1.97%48 472
CELLTRION, INC.-13.37%38 667
IQVIA HOLDINGS INC.6.35%36 230
SEAGEN INC.8.94%34 149
HANGZHOU TIGERMED CONSULTIN..7.64%21 275
INCYTE CORPORATION8.02%20 577
ALNYLAM PHARMACEUTICALS, IN..31.55%19 566
PHARMARON BEIJING CO., LTD.16.82%15 255
CRISPR THERAPEUTICS AG29.51%14 657
CHARLES RIVER LABORATORIES ..11.62%13 873
BIO-TECHNE CORPORATION12.32%13 582
QIAGEN N.V.1.87%12 316
ICON PUBLIC LIMITED COMPANY13.32%11 353
IONIS PHARMACEUTICALS, INC.10.61%8 533
More Results
Financials (USD)
Sales 2020 4 586 M - -
Net income 2020 140 M - -
Net Debt 2020 3 428 M - -
P/E ratio 2020 89,3x
Yield 2020 -
Capitalization 12 539 M 12 539 M -
EV / Sales 2020 3,48x
EV / Sales 2021 3,06x
Nbr of Employees 23 000
Free-Float 61,2%
Upcoming event on PPD, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality -
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes